• Home
  • |
  • Blog
  • |
  • Jeff Siegel’s EN-23 Stock Picks – The Next Big Breakthroughs?

Jeff Siegel’s EN-23 Stock Picks – The Next Big Breakthroughs?

Jeff Siegel’s EN-23 Stock Picks

March 19, 2024 by Theodor

What do Bill Gates, Nobel Prize winner Kary Mullis, and Joe Rogan all have in common?

They all take a “limitless pill” Jeff Siegel calls “EN-23” and early investors stand to make a fortune on the innovation.

 

The Teaser

For more than 50 years, the world’s richest and most powerful people have been taking this magic elixir to enhance their cognitive abilities and increase productivity.

Source: angelpub.com

The man behind this presentation, Jeff Siegel, has been an independent financial analyst for the past 25 years, focusing primarily on alternative energy sustainability, cannabis, and agriculture, so healthcare is a bit of a detour for him.

We have previously answered the question of whether Jeff is a complete fraud and we have also reviewed his Bigger Than Tesla” EV Company.

EN-23” isn't a new discovery. Its basic ingredient has been around for centuries, which lets us know that it works and wasn't something concocted in a lab, in a couple of months, and rolled out to the public.

Some scientists have even suggested a natural version of it played a role in the emergence of human language and consciousness in early hominids.

Besides being partially responsible for humankind, what else can this pill do? 

  • It can help us become physically fitter
  • Improve our sex lives
  • And extending our life span by as much as 20 years, among other cures

This sounds a lot like the fictional drug, NZT-48, from the movie Limitless starring Bradley Cooper.

But Jeff says EN-23 is real and “could be the most profitable drug in human history.”

Bigger Than Penicillin

Since its rollout in the early 1940s, the Penicillin antibiotic discovered by Alexander Fleming is credited with saving more than 200 million lives.

Jeff is confident EN-23 will save more and it could become available to the public in less than 12 months. Last summer phase III trials for EN-23 were completed, which is typically the last hurdle to clear before FDA approval.

EN-23 is so close to coming to market that the American Medical Association (AMA) has approved insurance billing codes for the drug.

It is being called a “world-changing breakthrough” and there are three stocks we can buy now to take advantage of this disruptive development.

 

The Pitch

Jeff has written not just one, but two detailed reports on what is being called the real-life “Limitless Pill.” The first report is aptly titled “EN-23: The Real-Life Limitless Pill” and the second report is called: “Three EN-23 Picks for Triple-Digit Gains.”

Source: angelpub.com

Both reports are ours with a membership to Jeff's invitation-only research service, Green Chip Stocks, which costs $299 for the first year.

A 90-day money-back guarantee is included, as is weekly insider intel on companies and industries Jeff is following, invitations to private research trips of his, and access to a password-protected website containing urgent stock alerts.

 

Why EN-23 Is Turning Traditional Medicine Upside Down

Traditional treatments of today could be better in at least a few ways.

For starters, they usually address only one disease at a time. They also take a long time to work, often have painful side effects, and are usually expensive.

To top it all off, they are only effective about 30% of the time.

This leaves multiple markets totaling more than $1 trillion ripe for disruption.

Enter EN-23, which could potentially treat an almost endless number of diseases with 60%-100% effectiveness with just a single dose.

What is EN-23 Exactly?

Jeff comes clean and admits EN-23 isn’t just a single pill or treatment.

Instead, it’s a valuable class of molecules that drastically improve brain function.

Digging deeper, these molecules bind to the serotonin 2a receptor, which is one of 15 specialized receptor molecules the serotonin system uses to coordinate brain activity.

In non-medical terms, EN-23 promotes neuroplasticity, which in turn can improve brain function.

To me, this sounds kind of like psychedelics, which are a known therapy for mental health.

According to a Dr. Halland Chen, a double board-certified physician who practices functional and regenerative medicine, psychedelics produce much more than just therapies for mental health and “may result in therapeutics for human longevity.”

It's such therapeutics that Jeff is teasing here.

Much like the penicillin class of antibiotics, which contain about 15 chemically related drugs and are now valued at nearly $9 billion, the same thing is now happening with EN-23, but the value of this market will easily exceed that of penicillin because it can treat so many different types of diseases and ailments. 

Figuring conservatively, Jeff believes we're looking at a market of more than $1 trillion. 

However, there isn't just one, but three EN-23 companies in particular that stand to get a sizable chunk of this action. Let's try and find out what they are.

 

Revealing Jeff Siegel's EN-23 Stock Picks

We only get about one paragraph or a single sentence worth of info on each pick, so this isn't going to be easy. Here is what we have to work with:

First EN-23 Pick

It is developing EN-23 treatments for major depressive disorder, anxiety, and alcoholism. The value of those three treatments alone exceeds $300 billion.

Second EN-23 Pick

Currently developing an EN-23-derived treatment for neuroinflammation.

Third EN-23 Pick

The third EN-23 company is a virtual gold mine that’s developing a new EN-23-derived treatment for chronic pain.

Jeff ends by saying “All three companies are flush with cash, are directly connected to the pharmaceutical industry, and have a diversified portfolio of drug development programs that are currently in FDA clinical trials.”

Based on this scant info, the following companies best fit Jeff's description:

  • First EN-23 Pick: MindMed Inc. (Nasdaq: MNMD). Per its own admission, the company is “dedicated to developing psychedelic-inspired medicines known as psychoplastogens and therapies to address addiction and mental illness”. Depression, anxiety, and alcoholism fall under this umbrella.
  • Second EN-23 Pick: Cybin Inc. (NYSE: CYBN) could be the pick here, based on one of its three active drug programs targeting neuroinflammation.
  • Third EN-23 Pick: This sounds like Atai Life Sciences N.V. (Nasdaq: ATAI), which has multiple therapeutics in various phases of the clinical trial process.

 

Fast Way to Triple-Digit Gains?

Psychedelics stocks were all the buzz a few years ago, is there now some substance behind the hype?

From the standpoint of Jeff's presumed stock picks, we are still at the mid-way point. Well past pre-clinical trials, but not yet at full FDA approval.

Two of the stocks mentioned above, MindMed and Cybin, were granted breakthrough therapy designations by the FDA. A process meant to expedite the review of drugs that have shown at least some promise in the trial phase.

Both stocks popped on these announcements earlier this month, with MindMed gaining over 50% and Cybin appreciating 40%.

However, to keep things in perspective this still means no revenue, which in turn means all three companies are entirely reliant on raising capital, and that entails some serious stock dilution for shareholders.

To get the triple-digit gains Jeff is talking about here, marketable drugs that people can buy will be needed and we are still more than a year away from that happening…if it happens at all.

I have said this before, but it bears repeating here. Pharma/Biotech investing is much closer to angel or venture capital investing (speculation) than buying into established businesses via the stock market.

It takes more than $1 billion to get through all three phases of clinical trials and only 12% of drugs that reach the clinical phase go to market, so it's not for the faint of heart.

The odds are decidedly against us, but if you want a trip, an ETF does provide exposure to the psychedelic drugs sector, it's called AdvisorShares Psychedelics ETF (NYSE: PSIL).

 

Quick Recap & Conclusion

  • Independent financial analyst Jeff Siegel is teasing a “limitless pill” called “EN-23.” An innovation on which early investors stand to make a fortune.
  • EN-23” refers to a class of molecules that drastically improve brain function and several companies are developing novel ways to tap into these molecules, which in turn can improve brain function.
  • Jeff has put together not just one, but two detailed reports revealing the names and ticker symbols of these innovators. The first report is “EN-23: The Real-Life Limitless Pill” and the second report is called: “Three EN-23 Picks for Triple-Digit Gains.”
  • Not many clues were provided, but based on what we read, we're fairly confident Jeff's three EN-23 stock picks are: MindMed Inc. (Nasdaq: MNMD), Cybin Inc. (NYSE: CYBN), and Atai Life Sciences N.V. (Nasdaq: ATAI).
  • All three picks are still pre-revenue, in the clinical trial phase, and more than a year away from any final approvals…if they ever get them at all. Thus, the best way to play the psychedelic drugs sector, if you're feeling like having an out-of-body and hopefully not an out-of-wallet experience, is with an ETF called AdvisorShares Psychedelics ETF (NYSE: PSIL).

Will psychedelics ever become mainstream therapeutics? Tell us what you think in the comments.

Theodor


Theodor is an old school value guy, when he's not looking for great companies and great prices you can find him on the basketball court hooping.

  • Very interesting, i’ve been hearing a lot about psychedelics recently, so I wasn’t surprised (Although a little disappointed, because I love the idea of a longevity medication, psychedelics not so much). I enjoyed your analysis and appreciate the warning that this could be a risky investment.

  • Recently my VA doctor spoke to me about how the VA is currently looking into psychedelics to treat combat PTSD. If it does get approved, this could potentially create a sizable market with federal government backing.

  • {"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}
    >